Published in Biol Psychiatry on March 27, 2013
A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry (2014) 1.69
Effects of striatal ΔFosB overexpression and ketamine on social defeat stress-induced anhedonia in mice. Biol Psychiatry (2014) 1.54
Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu Rev Pharmacol Toxicol (2014) 1.21
The role of ketamine in treatment-resistant depression: a systematic review. Curr Neuropharmacol (2014) 1.10
Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res (2014) 1.09
Ketamine as a promising prototype for a new generation of rapid-acting antidepressants. Ann N Y Acad Sci (2015) 1.04
Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry (2014) 1.00
Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. J Neural Transm (Vienna) (2013) 0.98
The habenula encodes negative motivational value associated with primary punishment in humans. Proc Natl Acad Sci U S A (2014) 0.95
Dysfunctional Reward Processing in Depression. Curr Opin Psychol (2015) 0.91
Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. J Psychopharmacol (2015) 0.91
Preliminary Findings Supporting Insula Metabolic Activity as a Predictor of Outcome to Psychotherapy and Medication Treatments for Depression. J Neuropsychiatry Clin Neurosci (2015) 0.83
Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder. Transl Psychiatry (2015) 0.83
The neuroscience of depression: implications for assessment and intervention. Behav Res Ther (2014) 0.83
Neural correlates of suicidal ideation and its reduction in depression. Int J Neuropsychopharmacol (2014) 0.82
New targets for rapid antidepressant action. Prog Neurobiol (2015) 0.81
Antidepressant-like cognitive and behavioral effects of acute ketamine administration associated with plasticity in the ventral hippocampus to medial prefrontal cortex pathway. Psychopharmacology (Berl) (2015) 0.81
Habenula functional resting-state connectivity in pediatric CRPS. J Neurophysiol (2013) 0.81
Disrupted habenula function in major depression. Mol Psychiatry (2016) 0.78
Chronic fluoxetine increases extra-hippocampal neurogenesis in adult mice. Int J Neuropsychopharmacol (2014) 0.78
Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine. Biol Psychiatry (2016) 0.77
Resting-state functional connectivity of the human habenula in healthy individuals: Associations with subclinical depression. Hum Brain Mapp (2016) 0.77
Ameliorating treatment-refractory depression with intranasal ketamine: potential NMDA receptor actions in the pain circuitry representing mental anguish. CNS Spectr (2015) 0.76
Circuits regulating pleasure and happiness: the evolution of reward-seeking and misery-fleeing behavioral mechanisms in vertebrates. Front Neurosci (2015) 0.76
Structural connectivity and response to ketamine therapy in major depression: A preliminary study. J Affect Disord (2015) 0.76
Ketamine Protects Gamma Oscillations by Inhibiting Hippocampal LTD. PLoS One (2016) 0.75
Preliminary differences in resting state MEG functional connectivity pre- and post-ketamine in major depressive disorder. Psychiatry Res (2016) 0.75
Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders. Curr Behav Neurosci Rep (2015) 0.75
A default mode of brain function. Proc Natl Acad Sci U S A (2001) 50.73
Fast robust automated brain extraction. Hum Brain Mapp (2002) 41.79
Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging (2001) 25.22
Medial prefrontal cortex and self-referential mental activity: relation to a default mode of brain function. Proc Natl Acad Sci U S A (2001) 14.86
A unified statistical approach for determining significant signals in images of cerebral activation. Hum Brain Mapp (1996) 13.15
Deep brain stimulation for treatment-resistant depression. Neuron (2005) 12.39
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry (2006) 11.84
mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science (2010) 10.97
Antidepressant effects of ketamine in depressed patients. Biol Psychiatry (2000) 10.91
Subgenual prefrontal cortex abnormalities in mood disorders. Nature (1997) 9.36
Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry (1999) 7.87
Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct (2008) 6.32
Neurocircuitry of mood disorders. Neuropsychopharmacology (2010) 5.57
Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci (1997) 5.30
Architectonic subdivision of the human orbital and medial prefrontal cortex. J Comp Neurol (2003) 5.13
Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol Psychiatry (2001) 5.11
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 4.46
Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch Gen Psychiatry (2004) 3.85
The subgenual anterior cingulate cortex in mood disorders. CNS Spectr (2008) 3.40
Emotion: clues from the brain. Annu Rev Psychol (1995) 3.21
Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry (2001) 3.18
Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity. Proc Natl Acad Sci U S A (1998) 3.17
Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress (1998) 3.07
Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry (2002) 3.01
Synaptic potentiation onto habenula neurons in the learned helplessness model of depression. Nature (2011) 2.98
Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13C NMR. Proc Natl Acad Sci U S A (1999) 2.76
Remission of major depression under deep brain stimulation of the lateral habenula in a therapy-refractory patient. Biol Psychiatry (2010) 2.71
Error monitoring using external feedback: specific roles of the habenular complex, the reward system, and the cingulate motor area revealed by functional magnetic resonance imaging. J Neurosci (2003) 2.59
Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropsychopharmacol (2002) 2.53
Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology (2012) 2.17
Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. Arch Gen Psychiatry (2006) 2.09
Relationship between amygdala responses to masked faces and mood state and treatment in major depressive disorder. Arch Gen Psychiatry (2010) 1.94
Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch Gen Psychiatry (2004) 1.92
Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry (2005) 1.84
Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol (1990) 1.82
Covariation of activity in habenula and dorsal raphé nuclei following tryptophan depletion. Neuroimage (1999) 1.65
Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry (2008) 1.64
Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry (1997) 1.64
Deep brain stimulation of the lateral habenula in treatment resistant major depression. Med Hypotheses (2007) 1.58
Lateral habenula lesions improve the behavioral response in depressed rats via increasing the serotonin level in dorsal raphe nucleus. Behav Brain Res (2007) 1.57
The role of the habenular complex in the elevation of dorsal raphe nucleus serotonin and the changes in the behavioral responses produced by uncontrollable stress. Brain Res (2001) 1.56
The effects of tryptophan depletion on neural responses to emotional words in remitted depression. Biol Psychiatry (2009) 1.50
Functional coupling of the amygdala in depressed patients treated with antidepressant medication. Neuropsychopharmacology (2007) 1.48
Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. Arch Gen Psychiatry (2008) 1.42
Emotion induction after direct intracerebral stimulations of human amygdala. Cereb Cortex (2006) 1.42
Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology. Mol Psychiatry (2012) 1.41
Increased self-focus in major depressive disorder is related to neural abnormalities in subcortical-cortical midline structures. Hum Brain Mapp (2009) 1.40
Cerebral correlates of depressed behavior in rats, visualized using 14C-2-deoxyglucose autoradiography. J Neurosci (1988) 1.38
Interpreting functional imaging studies in terms of neurotransmitter cycling. Proc Natl Acad Sci U S A (1998) 1.35
Schizophrenia in translation: the presence of absence: habenular regulation of dopamine neurons and the encoding of negative outcomes. Schizophr Bull (2006) 1.33
The BDNF Val66Met polymorphism impacts parahippocampal and amygdala volume in healthy humans: incremental support for a genetic risk factor for depression. Psychol Med (2009) 1.33
In vivo nuclear magnetic resonance spectroscopy studies of the relationship between the glutamate-glutamine neurotransmitter cycle and functional neuroenergetics. Philos Trans R Soc Lond B Biol Sci (1999) 1.32
Habenula volume in bipolar disorder and major depressive disorder: a high-resolution magnetic resonance imaging study. Biol Psychiatry (2010) 1.32
Opposite metabolic changes in the habenula and ventral tegmental area of a genetic model of helpless behavior. Brain Res (2003) 1.28
Antidepressant medications reduce subcortical-cortical resting-state functional connectivity in healthy volunteers. Neuroimage (2011) 1.26
Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav (2002) 1.24
Pharmacological inhibition of the lateral habenula improves depressive-like behavior in an animal model of treatment resistant depression. Behav Brain Res (2010) 1.23
Evidence for structural abnormalities of the human habenular complex in affective disorders but not in schizophrenia. Psychol Med (2009) 1.21
Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur J Pharmacol (1994) 1.20
Astrocytes Couple Synaptic Activity to Glucose Utilization in the Brain. News Physiol Sci (1999) 1.20
Neural markers of symptomatic improvement during antidepressant therapy in severe depression: subgenual cingulate and visual cortical responses to sad, but not happy, facial stimuli are correlated with changes in symptom score. J Psychopharmacol (2008) 1.17
Brain blood flow alterations induced by therapeutic vagus nerve stimulation in partial epilepsy: I. Acute effects at high and low levels of stimulation. Epilepsia (1998) 1.17
Dopamine agonists and stress produce different patterns of Fos-like immunoreactivity in the lateral habenula. Brain Res (1994) 1.15
Voxel-based analyses of gray/white matter volume and diffusion tensor data in major depression. Psychiatry Res (2010) 1.14
Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia. Neuropsychopharmacology (2005) 1.08
Role of the amygdala in antidepressant effects on hippocampal cell proliferation and survival and on depression-like behavior in the rat. PLoS One (2010) 1.02
Sequential regional cerebral blood flow brain scans using PET with H2(15)O demonstrate ketamine actions in CNS dynamically. Neuropsychopharmacology (2001) 1.02
Effort and stress influence the effect of lesion of the habenula complex in one-way active avoidance learning. Physiol Behav (1989) 1.01
Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist. Neuropharmacology (1997) 1.00
Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715). Pharmacol Biochem Behav (1995) 1.00
Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol (1993) 1.00
Mapping the central effects of ketamine in the rat using pharmacological MRI. Psychopharmacology (Berl) (2006) 0.93
Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats. Pharmacol Biochem Behav (1993) 0.91
Profiles of antidepressant activity with the Montgomery-Asberg Depression Rating Scale. Acta Psychiatr Scand Suppl (1985) 0.89
First episode drug-naïve major depressive disorder with panic disorder: gray matter deficits in limbic and default network structures. Eur Neuropsychopharmacol (2010) 0.88
Grey matter volume reductions in the emotion network of patients with depression and coronary artery disease. Psychiatry Res (2010) 0.83
Serotonin transporter genotype and depressive phenotype determination by discriminant analysis of glucose metabolism under acute tryptophan depletion. Neuroimage (2008) 0.83
Variation in asymmetry of the habenular nucleus correlates with behavioural asymmetry in a cichlid fish. Behav Brain Res (2011) 0.82
Effects of anesthesia upon 18F-FDG uptake in rhesus monkey brains. Ann Nucl Med (2005) 0.81
Drug-action profiles based on an abbreviated psychiatric rating scale. J Nerv Ment Dis (1960) 0.78
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry (2006) 11.84
Neurobiology of emotion perception I: The neural basis of normal emotion perception. Biol Psychiatry (2003) 6.93
Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry (2007) 6.59
Neurobiology of emotion perception II: Implications for major psychiatric disorders. Biol Psychiatry (2003) 6.52
Neurocircuitry of mood disorders. Neuropsychopharmacology (2010) 5.57
Discovering endophenotypes for major depression. Neuropsychopharmacology (2004) 4.90
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry (2010) 4.85
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 4.46
International Society for Bipolar Disorders Task Force on Suicide: meta-analyses and meta-regression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar Disord (2014) 4.10
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry (2007) 3.15
The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry (2003) 3.00
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry (2010) 2.98
Neural circuits underlying the pathophysiology of mood disorders. Trends Cogn Sci (2011) 2.76
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry (2012) 2.74
Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry (2006) 2.68
Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neurosci Biobehav Rev (2009) 2.44
Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther (2006) 2.41
Choosing the lesser of two evils, the better of two goods: specifying the roles of ventromedial prefrontal cortex and dorsal anterior cingulate in object choice. J Neurosci (2006) 2.40
The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci (2003) 2.28
Regional cerebral glucose utilization in patients with a range of severities of unipolar depression. Biol Psychiatry (2002) 2.26
Ketamine for depression: where do we go from here? Biol Psychiatry (2012) 2.21
Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology (2012) 2.17
Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci (2004) 2.17
Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. Arch Gen Psychiatry (2006) 2.09
Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry (2006) 2.09
Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry (2008) 2.05
Species-specific calls evoke asymmetric activity in the monkey's temporal poles. Nature (2004) 2.04
Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention. Sci STKE (2004) 2.04
Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry (2002) 2.01
5-HT(1A) receptor function in major depressive disorder. Prog Neurobiol (2009) 1.99
Tryptophan depletion alters the decision-making of healthy volunteers through altered processing of reward cues. Neuropsychopharmacology (2003) 1.99
Response to emotional expressions in generalized social phobia and generalized anxiety disorder: evidence for separate disorders. Am J Psychiatry (2008) 1.99
The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry (2013) 1.97
The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry (2010) 1.94
Volumetric reduction in left subgenual prefrontal cortex in early onset depression. Biol Psychiatry (2002) 1.94
Relationship between amygdala responses to masked faces and mood state and treatment in major depressive disorder. Arch Gen Psychiatry (2010) 1.94
Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. J Nucl Med (2013) 1.93
Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch Gen Psychiatry (2004) 1.92
The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav (2014) 1.90
Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther (2009) 1.90
Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology (2005) 1.90
Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement (2013) 1.87
Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry (2002) 1.86
Downregulation of brain phosphodiesterase type IV measured with 11C-(R)-rolipram positron emission tomography in major depressive disorder. Biol Psychiatry (2012) 1.85
Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry (2002) 1.84
A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry (2006) 1.83
Serotonin 1A receptor reductions in postpartum depression: a positron emission tomography study. Fertil Steril (2007) 1.82
Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol Psychiatry (2004) 1.82
AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol (2004) 1.79
Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology (2008) 1.79
A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry (2012) 1.76
Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord (2007) 1.74
Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry (2003) 1.72
Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry (2003) 1.71
An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry (2004) 1.71
Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry (2008) 1.71
Rapid and non-rapid cycling bipolar disorder: a meta-analysis of clinical studies. J Clin Psychiatry (2003) 1.68
An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry (2005) 1.65
Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology (2010) 1.65
Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry (2006) 1.65
Neural and behavioral substrates of mood and mood regulation. Biol Psychiatry (2002) 1.65
The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology (2006) 1.64
The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord (2009) 1.62